Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34362839.
- Also identified by DOI 10.1136/thoraxjnl-2021-217325 and PMC identifier 8762000.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Reduction of the risk of asthma attacks is a major goal of current asthma management. We propose to derive a risk scale predicting asthma attacks based on the blood eosinophil count and exhaled nitric oxide (FeNO). Biomarker-stratified trial-level attack rates were extracted and pooled from the control arms of the Novel START, CAPTAIN, QUEST, Benralizumab Phase 2b, PATHWAY, STRATOS 1-2 and DREAM trials (n=3051). These were used to derive rate ratios and the predicted asthma attack rate for different patient groups. The resultant prototype risk scale shows potential to predict asthma attacks, which may be prevented by anti-inflammatory treatment.
Medical subject headings
- Asthma
- Nitric Oxide